COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 20, 2025, before U.S. markets open. The company, known for its innovative non-animal-derived rhCollagen technology for tissue regeneration and medical aesthetics, will provide updates on its financial performance.
CollPlant Biotechnologies (NASDAQ: CLGN), un'azienda specializzata in medicina rigenerativa ed estetica, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per mercoled矛 20 agosto 2025, prima dell'apertura dei mercati statunitensi. La societ脿, nota per la sua innovativa tecnologia rhCollagen non derivata da animali per la rigenerazione dei tessuti e l'estetica medica, fornir脿 aggiornamenti sulle sue performance finanziarie.
CollPlant Biotechnologies (NASDAQ: CLGN), una empresa especializada en medicina regenerativa y est茅tica, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el mi茅rcoles 20 de agosto de 2025, antes de la apertura de los mercados estadounidenses. La compa帽铆a, conocida por su innovadora tecnolog铆a rhCollagen no derivada de animales para la regeneraci贸n de tejidos y est茅tica m茅dica, proporcionar谩 actualizaciones sobre su desempe帽o financiero.
CollPlant Biotechnologies (NASDAQ: CLGN)電� 鞛儩 鞚橅暀 氚� 氙胳毄 鞚橅暀鞚� 鞝勲鞙茧 頃橂姅 須岇偓搿�, 2025雲� 8鞗� 20鞚� 靾橃殧鞚� 氙戈淡 鞁滌灔 臧滌灔 鞝勳棎 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 霃欕 鞙犽灅臧� 鞎勲媽 順侅嫚鞝侅澑 rhCollagen 旮办垹鞚� 韱淀暣 臁办 鞛儩 氚� 鞚橂 氙胳毄 攵勳暭鞐愳劀 鞎岆牑歆� 鞚� 須岇偓電� 鞛 靹标臣鞐� 雽�頃� 鞐呺嵃鞚错姼毳� 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
CollPlant Biotechnologies (NASDAQ : CLGN), une entreprise sp茅cialis茅e dans la m茅decine r茅g茅n茅rative et esth茅tique, a programm茅 l'annonce de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le mercredi 20 ao没t 2025, avant l'ouverture des march茅s am茅ricains. La soci茅t茅, reconnue pour sa technologie innovante rhCollagen non d茅riv茅e d'animaux pour la r茅g茅n茅ration des tissus et l'esth茅tique m茅dicale, fournira des mises 脿 jour sur sa performance financi猫re.
CollPlant Biotechnologies (NASDAQ: CLGN), ein auf regenerative und 盲sthetische Medizin spezialisiertes Unternehmen, hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r Mittwoch, den 20. August 2025 geplant, und zwar vor 脰ffnung der US-M盲rkte. Das Unternehmen, bekannt f眉r seine innovative, nicht tierische rhCollagen-Technologie zur Geweberegeneration und medizinischen 脛sthetik, wird Updates zu seiner finanziellen Leistung geben.
- None.
- None.
REHOVOT,
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit听.
Contacts:
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: [email protected]听
Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]听
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
听
View original content:
SOURCE CollPlant
FAQ
When will CollPlant Biotechnologies (NASDAQ: CLGN) release Q2 2025 earnings?
What is CollPlant Biotechnologies' main business focus?
How can investors access CollPlant's Q2 2025 earnings report?
What type of technology does CollPlant Biotechnologies use?
